__NUXT_JSONP__("/drugs/Tirbanibulin", (function(a,b,c,d,e){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"Klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.",inn:b,marketingAuthorisationDate:"2021-07-16 00:00:00",marketingAuthorisationHolder:"Almirall, S.A.",medicineName:c,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fklisyri"}],fdaDrugLabel:[{brand:c,indication:"1 INDICATIONS AND USAGE KLISYRI is indicated for the topical treatment of actinic keratosis on the face or scalp. KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp. ( 1 )",manufacturer:"Almirall, LLC",splSetId:"589c8de8-b773-4d47-b60c-48471806cccc"}],id:a,nciThesaurus:{casRegistry:"897016-82-9",chebiId:d,chemicalFormula:d,definition:"An orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, tirbanibulin specifically binds to the peptide substrate binding site of Src kinase; inhibition of kinase activity may result in the inhibition of primary tumor growth and the suppression of metastasis. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis.",fdaUniiCode:"4V9848RS5G",identifier:"C74077",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C129825","C1967"],synonyms:["2-Pyridineacetamide, 5-(4-(2-(4-Morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-","KX01","KX2-391","TIRBANIBULIN",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FTirbanibulin",extension:".json",createdAt:e,updatedAt:e}}],fetch:{},mutations:void 0}}("Tirbanibulin","tirbanibulin","Klisyri","","2021-10-30T13:44:22.833Z")));